HC Wainwright Predicts Valneva’s Q1 Earnings (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Valneva in a research report issued on Thursday, January 23rd. HC Wainwright analyst E. White anticipates that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Valneva Trading Up 2.4 %

Shares of NASDAQ VALN opened at $4.74 on Friday. The stock’s fifty day moving average is $4.28 and its 200 day moving average is $5.80. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC raised its position in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.